S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
How the Wealthy Elite are Picking Stocks (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
How the Wealthy Elite are Picking Stocks (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
How the Wealthy Elite are Picking Stocks (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
How the Wealthy Elite are Picking Stocks (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
NASDAQ:AXSM

Axsome Therapeutics - AXSM Stock Forecast, Price & News

$44.62
+0.47 (+1.06%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$44.01
$46.57
50-Day Range
$36.06
$69.85
52-Week Range
$20.63
$71.98
Volume
1.09 million shs
Average Volume
1.10 million shs
Market Capitalization
$1.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$108.56

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
146.5% Upside
$110.00 Price Target
Short Interest
Healthy
17.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.75mentions of Axsome Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.35) to ($2.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

309th out of 1,093 stocks

Pharmaceutical Preparations Industry

139th out of 547 stocks

AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

8 Analysts Have This to Say About Axsome Therapeutics
2 No-Brainer Biotech Stocks to Buy Right Now
Axsome Therapeutics (NASDAQ:AXSM) Trading Down 5%
Is It Too Late to Buy Axsome Therapeutics Stock?
3 Top Healthcare Stocks Defying the Bear Market
Why Is Axsome (AXSM) Up 26.9% Since Last Earnings Report?
Mizuho Bolsters Price Target By 55% On This Migraine Stock
Analyst Ratings for Axsome Therapeutics
Expert Ratings for Axsome Therapeutics
3 Healthcare Stocks That Are Beating the Market
Why Axsome Therapeutics Stock Jumped This Week
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings
8/09/2022
Today
10/01/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$110.00
High Stock Price Forecast
$210.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+143.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-130,400,000.00
Pretax Margin
-1,699.89%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.41 per share

Miscellaneous

Free Float
28,796,000
Market Cap
$1.74 billion
Optionable
Optionable
Beta
1.68

Key Executives

  • Dr. Herriot Tabuteau M.D. (Age 54)
    Founder, Chairman, CEO & Pres
    Comp: $1.06M
  • Mr. Nick Pizzie CPAMr. Nick Pizzie CPA (Age 47)
    M.B.A., Chief Financial Officer
    Comp: $553.97k
  • Mr. Mark L. Jacobson (Age 39)
    COO & Sec.
    Comp: $554.72k
  • Mr. Hunter Murdock Esq.
    Exec. VP of Legal & Compliance
  • Dr. Amanda Jones Pharm.D. (Age 39)
    Sr. VP of Clinical Devel.
  • Ms. Lori Englebert M.B.A. (Age 44)
    Exec. VP of Commercial & Bus. Devel.
  • Mr. Kevin Laliberte Pharm.D. (Age 44)
    Exec. VP of Product Strategy
  • Joseph Debrah-Afful CPA
    M.B.A., Director of Fin.













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2022?

8 Wall Street analysts have issued 12-month price objectives for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $54.00 to $210.00. On average, they anticipate the company's share price to reach $110.00 in the next twelve months. This suggests a possible upside of 146.5% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2022?

Axsome Therapeutics' stock was trading at $37.78 at the beginning of the year. Since then, AXSM shares have increased by 18.1% and is now trading at $44.62.
View the best growth stocks for 2022 here
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings results on Tuesday, August, 9th. The company reported ($1.06) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.13. The firm earned $8.82 million during the quarter, compared to analysts' expectations of $9.59 million. During the same period in the previous year, the firm earned ($0.86) EPS.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $44.62.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $1.74 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 108 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.